BAFNAPH
Bafna Pharmaceuticals financials
- Market cap
- ₹738 Cr
- Sector
- Healthcare
What Bafna Pharmaceuticals Limited does
Bafna Pharmaceuticals manufactures generic pharmaceutical formulations (mainly tablets and capsules) at its UK-MHRA, TGA-Australia and EU/WHO-GMP certified facility in Chennai, and sells them under its own brands as well as on a contract basis for other pharma companies. It exports over 70% of its output across roughly 21 countries spanning the UK, Europe, Australia, Africa, CIS and South-East Asia. Beyond finished-dose manufacturing, it offers Contract Research & Manufacturing (CRAMS), technology transfer, and formulation and analytical development services, backed by an in-house DSIR-approved R&D centre that prepares regulatory dossiers for new market launches.
Segments
- Own-brand generics
- Contract Manufacturing (CMO/CRAMS)
- R&D / technology-transfer services
- Manufacturing facilities
- 2 units in Chennai (Madhavaram Unit-I; Grantlyon/Redhills Unit-II)
- Installed capacity - Tablets
- ~900 million units/year (~65% utilization in FY25)
- Installed capacity - Capsules
- ~375 million units/year (~80% utilization in FY25)
- Packaging lines capacity
- ~1,000 million units/year across 4 blister + 1 bottle line (~90% utilization in FY25)
- Employees
- 600+
- Export markets
- 21 countries across UK, Europe, Australia, Africa, CIS and SE Asia
Quarterly results
| Line item | Q1 FY19 | Q2 FY19 | Q1 FY20 | Q2 FY20 |
|---|---|---|---|---|
| Revenue | 12 | 9 | 7 | 12 |
| EBITDA | -2 | 0 | -3 | -0 |
| Net profit | -4 | -1 | -2 | -1 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +183.8% 1Y
1Y: ₹106.23 on 10 Sept 2025 → ₹301.45. High ₹312.6 (1 Sept 2026), low ₹99.16 (13 Mar 2026).
Balance sheet
| Year ending | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 |
|---|---|---|---|---|---|---|
| Equity capital | ₹19 Cr | ₹19 Cr | ₹19 Cr | ₹24 Cr | ₹24 Cr | ₹2 Cr |
| Reserves | ₹53 Cr | ₹39 Cr | ₹24 Cr | ₹14 Cr | ₹-5 Cr | ₹49 Cr |
| Borrowings | ₹69 Cr | ₹80 Cr | ₹82 Cr | ₹47 Cr | ₹46 Cr | ₹3 Cr |
| Other liabilities | ₹59 Cr | ₹54 Cr | ₹53 Cr | ₹54 Cr | ₹54 Cr | ₹17 Cr |
| Total liabilities | ₹200 Cr | ₹193 Cr | ₹178 Cr | ₹138 Cr | ₹119 Cr | ₹71 Cr |
| Fixed assets | ₹55 Cr | ₹53 Cr | ₹49 Cr | ₹45 Cr | ₹37 Cr | ₹35 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹128 Cr | ₹123 Cr | ₹113 Cr | ₹93 Cr | ₹82 Cr | ₹36 Cr |
| Total assets | ₹200 Cr | ₹193 Cr | ₹178 Cr | ₹138 Cr | ₹119 Cr | ₹71 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 3% to 7,062.
- Promoters
- 75.0%
- FIIs
- 9.3%
- Public
- 15.7%
Since Jun 2025
- Promoters 0.00 pp
- FIIs 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Over this window promoters fell from 88.7% to 75.0% — −13.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 88.7%, Public 11.3%.Dec '23: Promoters 88.4%, Public 11.6%.Mar '24: Promoters 88.3%, Public 11.7%.Jun '24: Promoters 88.3%, Public 11.7%.Sep '24: Promoters 88.3%, Public 11.7%.Dec '24: Promoters 88.3%, Public 11.7%.Mar '25: Promoters 75.0%, FIIs 8.5%, Public 16.5%.Jun '25: Promoters 75.0%, FIIs 9.3%, Public 15.7%.Sep '25: Promoters 75.0%, FIIs 9.3%, Public 15.7%.Dec '25: Promoters 75.0%, FIIs 9.3%, Public 15.7%.Mar '26: Promoters 75.0%, FIIs 9.3%, Public 15.7%.Jun '26: Promoters 75.0%, FIIs 9.3%, Public 15.7%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Bafna Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Srjr Lifesciences Llp | 74.57% | unchanged |
| M7 Global Fund Pcc-Aerion FPI fund | 3.21% | unchanged |
| M7 Global Fund Pcc - Cell Dewcap Fund FPI fund | 3.12% | unchanged |
| Zeal Global Opportunities Fund FPI fund | 3.01% | unchanged |
| Alpana Mundra | 2.73% | −0.52 pp |
| Monarch Networth Finserve Private Limited | 1.35% | unchanged |
| Guttikonda Vara Lakshmi | 1.29% | unchanged |
| P Paras Bafna | 0.21% | unchanged |
| Navin Bafna | 0.18% | unchanged |
| Mahaveer Chand Bafna | 0.03% | unchanged |
| Sasikala Bafna | 0.01% | unchanged |
| Amri Bai Bafna | 0.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Bafna Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.